This text offers state of the art contributions written by world renown experts which provide an extensive background on specific classes of antibiotics and summarize our understanding as to how these antibiotics might be optimally used in a clinical situation. The book explores pharmacodynamics methods for anti-infective agents, pharmacodynamics of antibacterial agents and non-antibacterial agents, as well as pharmacodynamic considerations and special populations. As part of the Methods in Pharmacology and Toxicology series, chapters include detailed insight and practical information for the lab. Comprehensive and cutting-edge, Antibiotic Pharmacodynamics serves as an ideal reference for scientists investigating advances in antibiotic pharmacodynamics now finding their way into the antibiotic development process used for licensing new antibiotics.

Within the past few years, it has become recognized that the immune system communicates to the brain. Substances released from activated immune cells (cytokines) stimulate peripheral nerves, thereby signaling the brain and spinal cord that infection/inflammation has occurred. Additionally, peripheral infection/inflammation leads to de novo synthesis and release of cytokines within the brain and spinal cord. Thus, cytokines effect neural activation both peripherally and centrally. Through this communication pathway, cytokines such as interleukin-1, interleukin-6 and tumor necrosis factor markedly alter brain function, physiology and behavior. One important but underrecognized aspect of this communication is the dramatic impact that immune activation has on pain modulation. The purpose of this book is to examine, for the first time, immune-to-brain communication from the viewpoint of its effect on pain processing. It is aimed both at the basic scientist and health care providers, in order to clarify the major role that substances released by immune cells play in pain modulation. This book contains chapters contributed by all of the major laboratories focused on understanding how cytokines modulate pain. These chapters provide a unique vantage point from which to examine this question, as the summarized work ranges from evolutionary approaches across diverse species, to the basics of the immune response, to the effect of cytokines on peripheral and central nervous system sites, to therapeutic potential in humans.

The introduction of chlorpromazine in 1953, and haloperidol in 1958, into clinical practice dramatically altered the therapy of schizophrenic patients. Although representing by no means a cure for this severe psychiatric ill ness, it allowed, for the first time, to adequately control the severe hallu cinations and delusional beliefs which prevent these patients from leading a more or less independent life. Indeed these antipsychotics (and the many congeners that were to follow) significantly reduced the number ofchronic schizophrenic inpatients in psychiatric clinics all over the world. However soon after their introduction it became clear that, like all other available drugs, antipsychotics were by no means miracle drugs. In fact, two major problems appeared. First, the antipsychotics had very little effect on the so-called negative or defect symptoms, like social isolation, apathy and anhedonia, and secondly virtually all antipsychotics produced a number of side-effects, of which the neurological (often called extra pyramidal) side-effects were the most troublesome. Especially the tardive dyskinesia, which occurred in about 15 to 20% of the patients after pro longed treatment, represented a major problem in the treatment of schizo phrenic patients."

Edward J. Massaro and a panel of leading biomedical researchers and clinical practitioners review, in-depth, the status of our current knowledge concerning the biochemistry of copper in general and its role in health and disease in particular. Drawing on the wealth of new information emerging from the molecular biology revolution, these experts survey the most important research areas of copper pharmacology and toxicology, including copper proteins and transport, copper toxicity and therapeutics, and copper metabolism and homeostasis. They also discuss the molecular pathogenesis of copper in a variety of metabolic diseases, Menkes and Wilson's diseases and occipital horn syndrome, as well as the role of copper in Parkinson's disease, prion disease, familial amytrophic lateral sclerosis (ALS), and Alzheimer's disease.

In the United States, 20.8 million children and adults, 7% of the population, have diabetes. While an estimated 14.6 million have been diagnosed, 6.2 million have yet to be diagnosed. Worldwide diabetes afflicts 150 million people. The World Health Organization estimates that by 2025 that figure will double. Diabetes is responsible for more deaths than AIDS and breast cancer, combined. It is a leading cause of blindness, kidney failure, amputations, heart complications and stroke. Treatment of Type 1 and Type diabetes has changed radically over the past few years. There are new opportunities for treating the key abnormality in diabetes, increased blood glucose, by effective agents such as new insulin preparations and oral agents. Increasing so-called non-glycemic intervention is of prime importance. Blood pressure lowering therapies, anti-cholesterol strategies, and specific treatment related to complications is becoming increasingly important. Pharmacotherapy of Diabetes is a unique, invaluable guide to all aspects of the pharmacological treatment of diabetes, covering basic concepts and an in-depth review of current and future therapies. This work provides an overview for the new changes in therapies that can be implemented in clinical practice and treatment of the diabetic patient.

The NATO Advanced Study Institute of "Molecular and Applied Aspects of Oxida- tive Drug Metabolizing Enzymes" was held in Tekirova, Antalya, Turkey, from August 31 to September 11, 1997. This Institute was the third of a series of the NATO ASIs on a similar topic relating to the enzymes of oxidative metabolism of xenobiotics. The first NATO ASI in this series, entitled "Molecular Aspects of Monooxygenases and Bioactiva- tion of Toxic Compounds" (NATO ASI Series A: Life Sciences, Vol. 202), was held in

Nitric Oxide (NO) is a pleitropic, ubiquitous modulator of cellular functions. Aryl nitrite and glyceryl trinitrate, representative intravasadilators, were introduced as therapeutic agents more than a century ago for relief from acute attacks of angina. The vasodilator action is mediated by the release of NO following treatment. NO has important therapeutic applications in several diseases such as inflammatory diseases, erectile dysfunction, inflammation, pain and neural protective activity. However, the role of NO in cancer and its application in therapy has received little attention. This monograph will be the first to focus on studies that investigate the role of NO in tumor cell pathogenesis, growth, angiogenesis, response to cytotoxic therapies and NO translational applications in cancer therapy, alone or in conjunction with other therapies.

F. Schweda and A. Kurtz: Regulation of Renin Release by Local and Systemic Factors M. Krauss and V. Haucke: Shaping Membranes for Endocytosis B.M. Jockusch and P.L. Graumann: The Long Journey: Actin on the Road to Pro- and Eukaryotic Cells B. Colsoul, R. Vennekens and B. Nilius: Transient Receptor Potential (TRP) Cation Channels in Pancreatic ss cells

A Pharmacology Primer: Techniques for More Effective and Strategic Drug Discovery, Sixth Edition features the latest research surrounding the application of pharmacology in drug discovery in an effort to equip readers with a deeper understanding of complex and rapid changes in this field. Written by well-respected pharmacologist, Terry P. Kenakin, this primer is an indispensable resource for anyone involved in drug discovery. This edition has been reorganized for better flow and clarity and includes material on new technologies for screening (virtual, DNA encoded libraires, fragment-based) and a major section on phenotypic (target agnostic) screening for new leads and determination of drug targets. With full color illustrations as well as new examples throughout, this book remains a top reference for all industry and academic scientists and students directly involved in drug discovery or pharmacologic research. New material includes a discussion of the determination of target engagement, including numerous new ways to demonstrate the physical interaction of molecules with drug targets and new drug candidates such a mRNA, gene therapy, antibodies and information on CRISPR and genomics.

Glyco-engineering is being developed as a method to control the composition of carbohydrates and to enhance the pharmacological properties of monoclonal antibodies (mAbs) and other proteins. In Glycosylation Engineering of Biopharmaceuticals: Methods and Protocols, experts in the field provide readers with production and characterization protocols of glycoproteins and glyco-engineered biopharmaceuticals with a focus on mAbs. The volume is divided in four complementary parts dealing with glyco-engineering of therapeutic proteins, glycoanalytics, glycoprotein complexes characterization, and PK/PD assays for therapeutic antibodies. Written in the highly successful Methods in Molecular Biology (TM) series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step, readily reproducible laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Authoritative and cutting-edge, Glycosylation Engineering of Biopharmaceuticals: Methods and Protocols serves as an ideal guide for scientists striving to push forward the exciting field of engineered biopharmaceuticals.

Biopharmaceutical medicines, the newest class of therapeutics, are quite heterogeneous and include a range of molecules such as proteins, peptides, vaccines and nucleic acids, with use in virtually all therapeutic fields (e.g. cancer and infectious diseases, vaccination, metabolic dysfunctions) and diagnostics. This edited book gives a concise and up-to-date overview of the biological features justifying the use of different human mucosa as delivery routes for biopharmaceuticals, the technological strategies that have been followed so far regarding the optimization of mucosal potentialities as well as the challenges that arise with the advent of new biopharmaceutical drugs and alternative means of administration. Following a brief introduction, the first section addresses general aspects of the biology of mucosal tissues and their unique aspects toward beneficial or deleterious interaction with biopharmaceuticals and their delivery systems. The second part reviews the different delivery strategies that have recently been investigated for different mucosal sites. The third section describes the development and clinical applications of drug delivery systems and products enclosing biopharmaceuticals for mucosal delivery, with a focus on the most successful case studies of recent years. The last section briefly centers on relevant aspects of the regulatory, toxicological and market issues of mucosal delivery of biopharmaceuticals. Scientists and researchers in the fields of drug delivery, material science, biomedical science and bioengineering as well as professionals, regulators and policy makers in the pharmaceutical, biotechnology and healthcare industries will find in this book an important compendium of fundamental concepts and practical tools for their daily research and activities.

This book highlights the behavioral and neurobiological issues relevant for drug development, reviews evidence for an innovative approach for drug discovery and presents perspectives on multiple special topics ranging from therapeutic drug use in children, emerging technologies and non-pharmacological approaches to cognitive enhancement.

This book provides an overview of historical and contemporary cases of homicidal poisoning. While homicidal poisoning is sometimes thought of as a thing of the past, it continues to be a contemporary problem, and in fact the unknown offender rate for poisoning cases is 20-30 times that of other homicide types in contemporary research, and many poisoners commit serial homicides while going undetected.The author of this important and timely work explores the theoretical bases for understanding homicidal poisoning, the nature of poisons used in homicidal cases, the characteristics of poisoners and their victims, and techniques for detection and prevention. This unique book will be of particular interest to: students of criminology (classes dealing with criminal psychology, and murder investigation); students of the history of crime; criminal justice professionals: attorneys, homicide detectives, forensic pathologists, forensic and clinical toxicologists, and other forensic investigators; and all interested in poisons, poisoners and the detection of poisoning. It has relevance to criminology, law and policing, toxicology and forensic science, the history of crime and detection, and criminal psychology. Endorsements: "A most welcomed addition to the important subject of the criminal poisoner. The author has done a fantastic job of researching the world literature, and distilling it down for the reader. The work is very well referenced, and provides critical information for law enforcement, forensic pathologists, and others, that could be dealing with the criminal poisoner." John H. Trestrail IIIToxicologistLos Lunas, New Mexico USA "Dr Michael Farrell has produced a comprehensive and authoritative work on a most serious but often overlooked aspect of criminal assault - the act of poisoning. In the Criminology of Homicidal Poisoning, Farrell seamlessly weaves together the facts about poisons and their use as an instrument of homicide with the context of the larger issue of murder. By examining the poisoner and the victim, the reader is provided a depth of understanding about how a deadly outcome arose and why the choice was made to employ poison to get the grisly job done. With criminal homicide by poisoning making up a small percentage of known crimes, the danger of insufficient scholarly attention is present. Dr Michael Farrell makes a significant contribution to ensure against this potential. As a homicide researcher, I know Criminology of Homicidal Poisoning will join the works I turn to in understanding the nuances of the how and why of homicide." Dr Richard M. Hough, Sr., Criminology and Criminal Justice and Public Administration Program Coordinator, University of West Florida, US "This comprehensive text links forensic toxicology with criminology, making a solid contribution to both fields. Farrell not only describes how homicidal poisoning fits the most popular criminological theories for why people kill but also examines the nature and lethality of various poisons, identifies trends in poisoning, provides a history, and shows offender traits and victim characteristics. In addition, he discusses issues for investigators and prosecutors who will be taking a poisoning case to trial." Katherine Ramsland Professor of forensic psychology at DeSales University, PennsylvaniaPsychology Today

Updated to include a succinct yet thorough review of the most recent evidence-based information and data-driven best treatment practices in child and adolescent psychiatry, this fourth edition of the Clinical Manual of Child and Adolescent Psychopharmacology not only examines the evidence for treating mental health disorders in younger patients but also illuminates how clinical trials of various methodologies can inform different aspects of clinical practice. Organized by DSM-5-TR diagnosis rather than drug class, this clinically accessible volume offers an exhaustive analysis of the use of psychotropic agents in disorders that include • Attention-deficit/hyperactivity disorder • Depressive disorders • Autism spectrum disorder • Early schizophrenia and psychotic illnesses • Eating disorders Comprehensive medication tables allow for easy reference of dosing, side effects, and tips for management. Additionally, key points at the conclusion of each chapter summarize essential information for treating clinicians. With a depth of information unmatched by any other guide, this new edition of the Clinical Manual of Child and Adolescent Psychopharmacology is an indispensable desktop reference for clinicians working with young patients.

An authority on anti-drug policy and crack since it became a popular street drug in the mid-1980s, Belenko traces the development of America's policy response in the context of changes in policy that were underway when crack first appeared. He summarizes the state of our knowledge about crack, its pharmacological properties, its use and effects on health and behavior, and its distribution. Moreover, he makes recommendations about policies to deal with the next drug epidemic. This empirical analysis and public policy study is intended for teachers, graduate students, researchers, practitioners, and policymakers in drug control and treatment, criminal justice law enforcement, and in public administration.

As the pharmaceutical industry continues to advance, new techniques in drug design are emerging. In order to deliver optimal care to patients, the development of innovative pharmacological techniques has become a widely studied topic. The Handbook of Research on Molecular Docking-Based Drug Design and Discovery investigates the evolution of pharmaceutical design and computational approaches in the field of molecular docking. Highlighting theoretical backgrounds and emergent research in the area of computer-assisted drug design, this publication is a pivotal source for professionals, researchers, medical chemists, pharmaceutical experts, and students interested in innovative practices and findings within the fields of computational chemistry and pharmaceutical sciences.

This unique book is the only one to discuss various new techniques developed to enhance the application of nanoparticulate drug delivery systems using surface modification of nanoparticles. The understanding of the surface characteristics nano-particles is growing significantly with the advent of new analytical techniques. Polymer chemistry is contributing to the development of many new versatile polymers which have abilities to accommodate many different, very reactive chemical groups, and can be used as a diagnostic tool, for better targeting, for more effective therapeutic results as well as for reducing the toxic and side effects of the drugs. Surface modification of such polymeric nanoparticles has been found by many scientists to enhance the application of nanoparticles and also allows the nano particles to carry specific drug molecule and disease /tumor specific antibodies which refine and improve drug delivery. Surface Modification of Nanoparticles for Targeted Drug Delivery is a collection essential information with various applications of surface modification of nanoparticles and their disease specific applications for therapeutic purposes.

There is a high demand for antimicrobials for the treatment of new and emerging microbial diseases. In particular, microbes developing multidrug resistance have created a pressing need to search for a new generation of antimicrobial agents, which are effective, safe and can be used for the cure of multidrug-resistant microbial infections. Nano-antimicrobials offer effective solutions for these challenges; the details of these new technologies are presented here.

The book includes chapters by an international team of experts. Chemical, physical, electrochemical, photochemical and mechanical methods of synthesis are covered. Moreover, biological synthesis using microbes, an option that is both eco-friendly and economically viable, is presented. The antimicrobial potential of different nanoparticles is also covered, bioactivity mechanisms are elaborated on, and several applications are reviewed in separate sections. Lastly, the toxicology of nano-antimicrobials is briefly assessed."

The field of eicosanoid metabolism and function continues to grow. Synthesis of the prostaglandins from essential fatty acids was first described by Bergstrom and Sarnuelsson in 1964. The thromboxanes were discovered in 1975, the prostacyclins, by Moncada and Vane, in 1976, and the leukotrienes by Samuelsson in 1979. A new class of biologically active arachidonic acid metabolites named lipoxins was announced by Bengt Samuelsson in May 1984. Since that time major advances have been made in the molecular biology of the eicosanoids including the cloning of prostaglandin synthases and 5, 12, and 15-lipoxygenases from several different species, including man. This volume, Prostaglandins, Leukotrienes, Lipoxins, and P AF: Their Mechanism of Action, Molecular Biology, and Clinical Applications contains most of the papers presented in the plenary sessions of the Xlth International Washington Spring Symposium on Health Sciences. The book is divided into six parts, each covering a different aspect of this rapidly expanding field, and contains a total of 42 chapters by an internationally recognized group of authors in each area. Part I contains 11 chapters and covers the molecular biology and enzymology of prostaglandins and leukotrienes. Chapter 1 by the Editor details new mechanisms for the antiinflammatory glucocorticoids involving translational control of the messenger RNA for prostaglandin synthase. Chapter 2 by Yamamoto describes the molecular evolution of two distinct mammalian 12-lipoxygenases.

Etienne-Emile Baulieu, the discoverer of neurosteroids, and a panel of distinguished scientists and clinical researchers exhaustively and critically review all facets of neurosteroids involved in behavior, stress, memory, depression, anxiety, aging of the brain, and neurodegenerative diseases. These contributors illuminate the role of neurosteroids in brain development and plasticity and detail their neuromodulatory influence on GABAA, ionotropic glutamate receptors, acetylcholine receptors, sigma receptors, and calcium channels. Clearly pointing the way toward novel pharmaceutical agents that may be of significant therapeutic value, particularly with regard to aging mental functions, Neurosteroids: A New Regulatory Function in the Nervous System offers neurobiologists, psychiatrists, neurosurgeons, pharmacologists, and geriatricians the first comprehensive, state-of-the-art review of these important bioactive molecules.

Part B explores protein degradation occuring in vivo during protein synthesis in cells, examines the isolation and purification of proteins, details protein use in organisms, and reviews techniques to enhance protein stability.

The Symposium on New Drugs provides for an annual forum for academic investigators, research and development personnel from the pharmaceutical and related health care industries, and members of the Food and Drug Administration to discuss important clinical research issues. The Tenth Annual Symposium on New Drugs addressed the problem of whether it was still appropriate to approve antihypertensive agents soley on the endpoint of lowering cuff blood pressure. The initial discussions at this symposium related to the approaches and methods to studying antihypertensive agents. Dr. William Frishman provided a detailed list of the new approaches to the treatment of hypertension and pointed out the many new concepts that are currently active in the development of many new antihypertensive agents. Dr. William White detailed the growing importance of ambulatory blood pressure monitoring to define hypertension and to determine the change in blood pressure due to pharmacologically active agents. Dr. Jay Cohn pointed out the flaws in using cuff blood pressure and detailed the potential virtues of using vascular compliance to identify patients requiring treatment for hypertension. Dr. Thomas Pickering also discussed the potential value of evaluating changes in left ventricular hypertrophy a finding which identifies high risk patients who need to be included in clinical trials. Dr. Michael Weber detailed the issues and suggested refinements in the approaches to clinical trial designs for antihypertensive agents and Dr. Raymond Lipicky discussed the definition of dose-duration and the role of non-Mem and Peak/Through measurements in defining an antihypertensive drug effect.

This detailed volume examines computer-aided drug discovery (CADD), a crucial component of modern drug discovery programs that is widely utilized to identity and optimize bioactive compounds for the development of new drugs. With a focus on the methods that are commonly used in the early stage of drug discovery, chapters explore computer simulation, structure prediction, conformational sampling, binding site mapping, docking and scoring, in silico screening, and fragment-based drug design. In addition to the state-of-the-art theoretical concept, this book also includes step-by-step, readily reproducible computational protocols as well as examples of various CADD strategies. The limitations and potential pitfalls of different computational methods are discussed by experts, and tips and advice for their applications are suggested. Practical and thorough, Computer-Aided Drug Discovery serves as an ideal addition to the Methods in Pharmacology and Toxicology series, guiding researchers toward their lab's goals with this exciting and versatile technology.